In this study, we demonstrated that ulixertinib, a specific ERK inhibitor, effectively inhibits NB cell proliferation, promotes apoptosis, and sensitizes NB to doxorubicin, partially through downregulating c-Myc/N-Myc and other key signaling pathways. Here, MYCN is linked to neuroblastoma.